Skip to main content
NCBI home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2009 Oct;6(4):663–678. doi: 10.1016/j.nurt.2009.08.001

Sodium channel blockers for the treatment of neuropathic pain

Anindya Bhattacharya 1, Alan D Wickenden 1, Sandra R Chaplan 1,✉
PMCID: PMC5084288  PMID: 19789071

Summary

Drugs that block voltage-gated sodium channels are efficacious in the management of neuropathic pain. Accordingly, this class of ion channels has been a major focus of analgesic research both in academia and in the pharmaceutical/biotechnology industry. In this article, we review the history of the use of sodium channel blockers, describe the current status of sodium channel drug discovery, highlight the challenges and hurdles to attain sodium channel subtype selectivity, and review the potential usefulness of selective sodium channel blockers in neuropathic pain.

Key Words: Sodium channel, subtype, selectivity, neuropathic pain, drug discovery

References

  • 1.Mitchell SW. Gunshot Wounds and Other Injuries of Nerves. Philadelphia: Lippincott; 1864. [DOI] [PubMed] [Google Scholar]
  • 2.Rivera MA, Aufderheide AC, Cartmell LW, Torres CM, Langsjoen O. Antiquity of coca-leaf chewing in the south central Andes: a 3,000 year archaeological record of coca-leaf chewing from northern Chile. J Psychoactive Drugs. 2005;37:455–458. doi: 10.1080/02791072.2005.10399820. [DOI] [PubMed] [Google Scholar]
  • 3.Fairley HB. Anesthesia in the Inca empire. Rev Esp Anestesiol Reanim. 2007;54:556–562. [PubMed] [Google Scholar]
  • 4.Gaedcke F. Ueber das Erythroxylin, dargestellt aus den Blattern des in Sudamerika cultivirten Strauches Erythroxylon Coca Lam. Archiv der Pharmazie. 1855;132:141–150. doi: 10.1002/ardp.18551320208. [DOI] [Google Scholar]
  • 5.Ruetsch YA, Boni T, Borgeat A. From cocaine to ropivacaine: the history of local anesthetic drugs. Curr Top Med Chem. 2001;1:175–182. doi: 10.2174/1568026013395335. [DOI] [PubMed] [Google Scholar]
  • 6.Jones AE. Sigmund Freud: Life and Work. London: Hogarth Press; 1953. [Google Scholar]
  • 7.Cocaine Chemistry and New Local Anesthetics. Cal West Med 1926;25:232-233. [PMC free article] [PubMed]
  • 8.Taylor IB, Marks BW, Edmonds G. Intravenous administration of procaine hydrochloride during general anesthesia. Arch Surg. 1949;59:714–723. doi: 10.1001/archsurg.1949.01240040722031. [DOI] [PubMed] [Google Scholar]
  • 9.Phillips OC, Lyons WB, Harris LC, Nelson AT, Graff TD, Frazier TM. Intravenous lidocaine as an adjunct to general anesthesia: a clinical evaluation. Anesth Analg. 1960;39:317–322. [PubMed] [Google Scholar]
  • 10.Bigelow N, Harrison I. General analgesic effects of procaine. J Pharmacol Exp Ther. 1944;81:368–373. [Google Scholar]
  • 11.Lemoyne J. Use of dimethyl-dithio-hydantoin in treatment of certain facial neuralgias. Ann Otolaryngol. 1950;67:626–628. [PubMed] [Google Scholar]
  • 12.Kugelberg E, Lindblom U. The mechanism of the pain in trigeminal neuralgia. J Neurol Neurosurg Psychiatry. 1959;22:36–43. doi: 10.1136/jnnp.22.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Blom S. Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-32883) Lancet. 1962;1:839–840. doi: 10.1016/S0140-6736(62)91847-0. [DOI] [PubMed] [Google Scholar]
  • 14.Vaughan Williams EM. Classification of antidysrhythmic drugs. Pharmacol Ther [B] 1975;1:115–138. doi: 10.1016/0306-039x(75)90019-7. [DOI] [PubMed] [Google Scholar]
  • 15.Desanctis RW. Electrical Conversion of Ventricular Tachycardia. Jama. 1965;191:632–636. doi: 10.1001/jama.1965.03080080022005. [DOI] [PubMed] [Google Scholar]
  • 16.Carden NL, Steinhaus JE. Lidocaine in cardiac resuscitation from ventricular fibrillation. Circ Res. 1956;4:680–683. doi: 10.1161/01.res.4.6.680. [DOI] [PubMed] [Google Scholar]
  • 17.Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984;24:129–147. doi: 10.1002/j.1552-4604.1984.tb01822.x. [DOI] [PubMed] [Google Scholar]
  • 18.Loeser JD, Ward AA, White LE. Chronic deafferentation of human spinal cord neurons. J Neurosurg. 1968;29:48–50. doi: 10.3171/jns.1968.29.1.0048. [DOI] [PubMed] [Google Scholar]
  • 19.Burchiel KJ, Wyler AR. Ectopic action potential generation in peripheral trigeminal axons. Exp Neurol. 1978;62:269–281. doi: 10.1016/0014-4886(78)90057-2. [DOI] [PubMed] [Google Scholar]
  • 20.Boas RA, Covino BG, Shahnarian A. Analgesic responses to i.v. lignocaine. Br J Anaesth. 1982;54:501–505. doi: 10.1093/bja/54.5.501. [DOI] [PubMed] [Google Scholar]
  • 21.Petersen P, Kastrup J. Dercum’s disease (adiposis dolorosa). Treatment of the severe pain with intravenous lidocaine. Pain. 1987;28:77–80. doi: 10.1016/0304-3959(87)91062-1. [DOI] [PubMed] [Google Scholar]
  • 22.Kastrup J, Petersen P, Dejgard A, Angelo HR, Hilsted J. Intravenous lidocaine infusion—a new treatment of chronic painful diabetic neuropathy? Pain. 1987;28:69–75. doi: 10.1016/0304-3959(87)91061-X. [DOI] [PubMed] [Google Scholar]
  • 23.Lindstrom P, Lindblom U. The analgesic effect of tocainide in trigeminal neuralgia. Pain. 1987;28:45–50. doi: 10.1016/0304-3959(87)91058-X. [DOI] [PubMed] [Google Scholar]
  • 24.Dejgard A, Petersen P, Kastrup J. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet. 1988;1:9–11. doi: 10.1016/S0140-6736(88)90999-3. [DOI] [PubMed] [Google Scholar]
  • 25.Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J. Amitriptyline versus placebo in postherpetic neuralgia. Neurology. 1982;32:671–673. doi: 10.1212/wnl.32.6.671. [DOI] [PubMed] [Google Scholar]
  • 26.Leijon G, Boivie J. Central post-stroke pain—a controlled trial of amitriptyline and carbamazepine. Pain. 1989;36:27–36. doi: 10.1016/0304-3959(89)90108-5. [DOI] [PubMed] [Google Scholar]
  • 27.Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology. 1998;51:1166–1171. doi: 10.1212/wnl.51.4.1166. [DOI] [PubMed] [Google Scholar]
  • 28.Pancrazio JJ, Kamatchi GL, Roscoe AK, Lynch C. Inhibition of neuronal Na+ channels by antidepressant drugs. J Pharmacol Exp Ther. 1998;284:208–214. [PubMed] [Google Scholar]
  • 29.Barber MJ, Starmer CF, Grant AO. Blockade of cardiac sodium channels by amitriptyline and diphenylhydantoin. Evidence for two use-dependent binding sites. Circ Res. 1991;69:677–696. doi: 10.1161/01.res.69.3.677. [DOI] [PubMed] [Google Scholar]
  • 30.Dick IE, Brochu RM, Purohit Y, Kaczorowski GJ, Martin WJ, Priest BT. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J Pain. 2007;8:315–324. doi: 10.1016/j.jpain.2006.10.001. [DOI] [PubMed] [Google Scholar]
  • 31.Govrin-Lippmann R, Devor M. Ongoing activity in severed nerves: source and variation with time. Brain Res. 1978;159:406–410. doi: 10.1016/0006-8993(78)90548-6. [DOI] [PubMed] [Google Scholar]
  • 32.Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33:87–107. doi: 10.1016/0304-3959(88)90209-6. [DOI] [PubMed] [Google Scholar]
  • 33.Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain. 1990;43:205–218. doi: 10.1016/0304-3959(90)91074-S. [DOI] [PubMed] [Google Scholar]
  • 34.Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain. 1992;50:355–363. doi: 10.1016/0304-3959(92)90041-9. [DOI] [PubMed] [Google Scholar]
  • 35.Kajander KC, Wakisaka S, Bennett GJ. Spontaneous discharge originates in the dorsal root ganglion at the onset of a painful peripheral neuropathy in the rat. Neurosci Lett. 1992;138:225–228. doi: 10.1016/0304-3940(92)90920-3. [DOI] [PubMed] [Google Scholar]
  • 36.Devor M, Wall PD, Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain. 1992;48:261–268. doi: 10.1016/0304-3959(92)90067-L. [DOI] [PubMed] [Google Scholar]
  • 37.Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res. 2002;27:121–130. doi: 10.1023/A:1014814924965. [DOI] [PubMed] [Google Scholar]
  • 38.Tecoma ES. Oxcarbazepine. Epilepsia. 1999;40(Suppl 5):S37–46. doi: 10.1111/j.1528-1157.1999.tb00918.x. [DOI] [PubMed] [Google Scholar]
  • 39.Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain. 2005;9:543–554. doi: 10.1016/j.ejpain.2004.11.006. [DOI] [PubMed] [Google Scholar]
  • 40.Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand. 2006;114:177–180. doi: 10.1111/j.1600-0404.2005.00559.x. [DOI] [PubMed] [Google Scholar]
  • 41.Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008;73:157–169. doi: 10.1124/mol.107.039867. [DOI] [PubMed] [Google Scholar]
  • 42.Wallace MS, Rowbotham M, Bennett GJ, Jensen TS, Pladna R, Quessy S. A multicenter, double-blind, randomized, placebo-controlled crossover evaluation of a short course of 4030W92 in patients with chronic neuropathic pain. J Pain. 2002;3:227–233. doi: 10.1054/jpai.2002.123650. [DOI] [PubMed] [Google Scholar]
  • 43.Hagen NA, du Souich P, Lapointe B, et al. Tetrodotoxin for moderate to severe cancer pain: a randomized, double blind, parallel design multicenter study. J Pain Symptom Manage. 2008;35:420–429. doi: 10.1016/j.jpainsymman.2007.05.011. [DOI] [PubMed] [Google Scholar]
  • 44.Bach FW, Jensen TS, Kastrup J, Stigsby B, Dejgard A. The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy. Pain. 1990;40:29–34. doi: 10.1016/0304-3959(90)91047-M. [DOI] [PubMed] [Google Scholar]
  • 45.Ragsdale DS, McPhee JC, Scheuer T, Catterall WA. Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. Proc Natl Acad Sci U S A. 1996;93:9270–9275. doi: 10.1073/pnas.93.17.9270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Wagner LE, Eaton M, Sabnis SS, Gingrich KJ. Meperidine and lidocaine block of recombinant voltage-dependent Na+ channels: evidence that meperidine is a local anesthetic. Anesthesiology. 1999;91:1481–1490. doi: 10.1097/00000542-199911000-00042. [DOI] [PubMed] [Google Scholar]
  • 47.Wagner LE, Gingrich KJ, Kulli JC, Yang J. Ketamine blockade of voltage-gated sodium channels: evidence for a shared receptor site with local anesthetics. Anesthesiology. 2001;95:1406–1413. doi: 10.1097/00000542-200112000-00020. [DOI] [PubMed] [Google Scholar]
  • 48.Wang GK, Russell C, Wang SY. State-dependent block of voltage-gated Na+ channels by amitriptyline via the local anesthetic receptor and its implication for neuropathic pain. Pain. 2004;110:166–174. doi: 10.1016/j.pain.2004.03.018. [DOI] [PubMed] [Google Scholar]
  • 49.Yarov-Yarovoy V, Brown J, Shatp EM, Clare JJ, Scheuer T, Catterall WA. Molecular determinants of voltage-dependent gating and binding of pore-blocking drugs in transmembrane segment IIIS6 of the Na(+) channel alpha subunit. J Biol Chem. 2001;276:20–27. doi: 10.1074/jbc.M006992200. [DOI] [PubMed] [Google Scholar]
  • 50.Starmer CF, Grant AO, Strauss HC. Mechanisms of use-dependent block of sodium channels in excitable membranes by local anesthetics. Biophys J. 1984;46:15–27. doi: 10.1016/S0006-3495(84)83994-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Schwarz W, Palade PT, Hille B. Local anesthetics. Effect of pH on use-dependent block of sodium channels in frog muscle. Biophys J. 1977;20:343–368. doi: 10.1016/S0006-3495(77)85554-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Courtney KR. Mechanism of frequency-dependent inhibition of sodium currents in frog myelinated nerve by the lidocaine derivative GEA. J Pharmacol Exp Ther. 1975;195:225–236. [PubMed] [Google Scholar]
  • 53.Hille B. Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol. 1977;69:497–515. doi: 10.1085/jgp.69.4.497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Hondeghem LM, Katzung BG. Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. Annu Rev Pharmacol Toxicol. 1984;24:387–423. doi: 10.1146/annurev.pa.24.040184.002131. [DOI] [PubMed] [Google Scholar]
  • 55.Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XXXIX. Compendium of voltage-gated ion channels: sodium channels. Pharmacol Rev. 2003;55:575–578. doi: 10.1124/pr.55.4.7. [DOI] [PubMed] [Google Scholar]
  • 56.Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and Structure-Function Relationships of Voltage-Gated Sodium Channels. Pharmacol Rev. 2005;57:397–409. doi: 10.1124/pr.57.4.4. [DOI] [PubMed] [Google Scholar]
  • 57.Catterall WA, Cestele S, Yarov-Yarovoy V, Yu FH, Konoki K, Scheuer T. Voltage-gated ion channels and gating modifier toxins. Toxicon. 2007;49:124–141. doi: 10.1016/j.toxicon.2006.09.022. [DOI] [PubMed] [Google Scholar]
  • 58.Bosmans F, Tytgat J. Voltage-gated sodium channel modulation by scorpion alpha-toxins. Toxicon. 2007;49:142–158. doi: 10.1016/j.toxicon.2006.09.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Wang J, Ou SW, Wang YJ, Kameyama M, Kameyama A, Zong ZH. Analysis of four novel variants of Nav1.5/SCN5A cloned from the brain. Neurosci Res 2009. [DOI] [PubMed]
  • 60.Ragsdale DS. How do mutant Navl.l sodium channels cause epilepsy? Brain Res Rev. 2008;58:149–159. doi: 10.1016/j.brainresrev.2008.01.003. [DOI] [PubMed] [Google Scholar]
  • 61.Vahedi K, Depienne C, Le Fort D, et al. Elicited repetitive daily blindness: a new phenotype associated with hemiplegic migraine and SCN1A mutations. Neurology. 2009;72:1178–1183. doi: 10.1212/01.wnl.0000345393.53132.8c. [DOI] [PubMed] [Google Scholar]
  • 62.Scalmani P, Rusconi R, Armatura E, et al. Effects in neocortical neurons of mutations of the Na(v)1.2 Na+ channel causing benign familial neonatal-infantile seizures. J Neurosci. 2006;26:10100–10109. doi: 10.1523/JNEUROSCI.2476-06.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Colosimo E, Gambardella A, Mantegazza M, et al. Electroclinical features of a family with simple febrile seizures and temporal lobe epilepsy associated with SCN1A loss-of-function mutation. Epilepsia. 2007;48:1691–1696. doi: 10.1111/j.1528-1167.2007.01153.x. [DOI] [PubMed] [Google Scholar]
  • 64.Fujiwara T. Clinical spectrum of mutations in SCN1A gene: severe myoclonic epilepsy in infancy and related epilepsies. Epilepsy Res. 2006;70(Suppl 1):S223–230. doi: 10.1016/j.eplepsyres.2006.01.019. [DOI] [PubMed] [Google Scholar]
  • 65.Fujiwara T, Sugawara T, Mazald-Miyazaki E, et al. Mutations of sodium channel alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures. Brain. 2003;126:531–546. doi: 10.1093/brain/awg053. [DOI] [PubMed] [Google Scholar]
  • 66.Lossin C. A catalog of SCN1A variants. Brain Dev. 2009;31:114–130. doi: 10.1016/j.braindev.2008.07.011. [DOI] [PubMed] [Google Scholar]
  • 67.Lossin C, Rhodes TH, Desai RR, et al. Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. J Neurosci. 2003;23:11289–11295. doi: 10.1523/JNEUROSCI.23-36-11289.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Mantegazza M, Gambardella A, Rusconi R, et al. Identification of an Nav1.1 sodium channel (SCN1A) loss-of-function mutation associated with familial simple febrile seizures. Proc Natl Acad Sci U S A. 2005;102:18177–18182. doi: 10.1073/pnas.0506818102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Meisler MH, Kearney JA. Sodium channel mutations in epilepsy and other neurological disorders. J Clin Invest. 2005;115:2010–2017. doi: 10.1172/JCI25466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Sugawara T, Mazald-Miyazaki E, Fukushima K, et al. Frequent mutations of SCN1A in severe myoclonic epilepsy in infancy. Neurology. 2002;58:1122–1124. doi: 10.1212/wnl.58.7.1122. [DOI] [PubMed] [Google Scholar]
  • 71.Vanoye CG, Lossin C, Rhodes TH, George AL. Single-channel properties of human NaV1.1 and mechanism of channel dysfunction in SCN1A-associated epilepsy. J Gen Physiol. 2006;127:1–14. doi: 10.1085/jgp.200509373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Jurkat-Rott K, Lehmann-Horn F. Genotype-phenotype correlation and therapeutic rationale in hyperkalemic periodic paralysis. Neurotherapeutics. 2007;4:216–224. doi: 10.1016/j.nurt.2007.02.001. [DOI] [PubMed] [Google Scholar]
  • 73.Lehmann-Horn F, Jurkat-Rott K, Rudel R. Periodic paralysis: understanding channelopathies. Curr Neurol Neurosci Rep. 2002;2:61–69. doi: 10.1007/s11910-002-0055-9. [DOI] [PubMed] [Google Scholar]
  • 74.Sternberg D, Maisonobe T, Jurkat-Rott K, et al. Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain. 2001;124:1091–1099. doi: 10.1093/brain/124.6.1091. [DOI] [PubMed] [Google Scholar]
  • 75.Rogart RB, Cribbs LL, Muglia LK, Kephart DD, Kaiser MW. Molecular cloning of a putative tetrodotoxin-resistant rat heart Na+ channel isoform. Proc Natl Acad Sci U S A. 1989;86:8170–8174. doi: 10.1073/pnas.86.20.8170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Remme CA, Wilde AA, Bezzina CR. Cardiac sodium channel overlap syndromes: different faces of SCN5A mutations. Trends Cardiovasc Med. 2008;18:78–87. doi: 10.1016/j.tcm.2008.01.002. [DOI] [PubMed] [Google Scholar]
  • 77.Zimmer T, Surber R. SCN5A channelopathies—an update on mutations and mechanisms. Prog Biophys Mol Biol. 2008;98:120–136. doi: 10.1016/j.pbiomolbio.2008.10.005. [DOI] [PubMed] [Google Scholar]
  • 78.McKinney BC, Chow CY, Meisler MH, Murphy GG. Exaggerated emotional behavior in mice heterozygous null for the sodium channel Scn8a (Nav1.6) Genes Brain Behav. 2008;7:629–638. doi: 10.1111/j.1601-183X.2008.00399.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Chen YH, Dale TJ, Romanos MA, Whitaker WR, Xie XM, Clare JJ. Cloning, distribution and functional analysis of the type III sodium channel from human brain. Eur J Neurosci. 2000;12:4281–4289. [PubMed] [Google Scholar]
  • 80.Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain. 2004;108:237–247. doi: 10.1016/j.pain.2003.12.035. [DOI] [PubMed] [Google Scholar]
  • 81.Dib-Hajj SD, Fjell J, Cummins TR, et al. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain. 1999;83:591–600. doi: 10.1016/S0304-3959(99)00169-4. [DOI] [PubMed] [Google Scholar]
  • 82.Waxman SG, Kocsis JD, Black JA. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J Neurophysiol. 1994;72:466–470. doi: 10.1152/jn.1994.72.1.466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Cummins TR, Waxman SG. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury. J Neurosci. 1997;17:3503–3514. doi: 10.1523/JNEUROSCI.17-10-03503.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Fukuoka T, Kobayashi K, Yamanaka H, Obata K, Dai Y, Noguchi K. Comparative study of the distribution of the alpha-subunits of voltage-gated sodium channels in normal and axotomized rat dorsal root ganglion neurons. J Comp Neurol. 2008;510:188–206. doi: 10.1002/cne.21786. [DOI] [PubMed] [Google Scholar]
  • 85.Zhao P, Waxman SG, Hains BC. Sodium channel expression in the ventral posterolateral nucleus of the thalamus after peripheral nerve injury. Mol Pain. 2006;2:27–27. doi: 10.1186/1744-8069-2-27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Guo F, Yu N, Cai JQ, et al. Voltage-gated sodium channel Nav1.1, Nav1.3 and beta1 subunit were up-regulated in the hippocampus of spontaneously epileptic rat. Brain Res Bull. 2008;75:179–187. doi: 10.1016/j.brainresbull.2007.10.005. [DOI] [PubMed] [Google Scholar]
  • 87.Bartolomei F, Gastaldi M, Massacrier A, Planells R, Nicolas S, Cau P. Changes in the mRNAs encoding subtypes I, II and III sodium channel alpha subunits following kainate-induced seizures in rat brain. J Neurocytol. 1997;26:667–678. doi: 10.1023/A:1018549928277. [DOI] [PubMed] [Google Scholar]
  • 88.Nassar MA, Baker MD, Levato A, et al. Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice. Mol Pain. 2006;2:33–33. doi: 10.1186/1744-8069-2-33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Hains BC, Saab CY, Klein JP, Craner MJ, Waxman SG. Altered sodium channel expression in second-order spinal sensory neurons contributes to pain after peripheral nerve injury. J Neurosci. 2004;24:4832–4839. doi: 10.1523/JNEUROSCI.0300-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Lindia JA, Kohler MG, Martin WJ, Abbadie C. Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats. Pain. 2005;117:145–153. doi: 10.1016/j.pain.2005.05.027. [DOI] [PubMed] [Google Scholar]
  • 91.Sangameswaran L, Fish LM, Koch BD, et al. A novel tetrodotoxin-sensitive, voltage-gated sodium channel expressed in rat and human dorsal root ganglia. J Biol Chem. 1997;272:14805–14809. doi: 10.1074/jbc.272.23.14805. [DOI] [PubMed] [Google Scholar]
  • 92.Toledo-Aral JJ, Moss BL, He ZJ, et al. Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. Proc Natl Acad Sci U S A. 1997;94:1527–1532. doi: 10.1073/pnas.94.4.1527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Thakor DK, Lin A, Matsuka Y, et al. Increased peripheral nerve excitability and local NaV1.8 mRNA up-regulation in painful neuropathy. Mol Pain. 2009;5:14–14. doi: 10.1186/1744-8069-5-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Kretschmer T, Happel LT, England JD, et al. Accumulation of PN1 and PN3 sodium channels in painful human neuroma-evidence from immunocytochemistry. Acta Neurochir (Wien) 2002;144:803–810. doi: 10.1007/s00701-002-0970-1. [DOI] [PubMed] [Google Scholar]
  • 95.Cummins TR, Howe JR, Waxman SG. Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J Neurosci. 1998;18:9607–9619. doi: 10.1523/JNEUROSCI.18-23-09607.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Nassar MA, Stirling LC, Forlani G, et al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci U S A. 2004;101:12706–12711. doi: 10.1073/pnas.0404915101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Nassar MA, Levato A, Stirling LC, Wood JN. Neuropathic pain develops normally in mice lacking both Nav1.7 and Nav1.8. Mol Pain. 2005;1:24–24. doi: 10.1186/1744-8069-1-24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Djouhri L, Fang X, Okuse K, Wood JN, Berry CM, Lawson SN. The TTX-resistant sodium channel Nav1.8 (SNS/PN3): expression and correlation with membrane properties in rat nociceptive primary afferent neurons. J Physiol. 2003;550:739–752. doi: 10.1113/jphysiol.2003.042127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Devor M. Ectopic discharge in Abeta afferents as a source of neuropathic pain. Exp Brain Res. 2009;196:115–128. doi: 10.1007/s00221-009-1724-6. [DOI] [PubMed] [Google Scholar]
  • 100.Fertleman CR, Baker MD, Parker KA, et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron. 2006;52:767–774. doi: 10.1016/j.neuron.2006.10.006. [DOI] [PubMed] [Google Scholar]
  • 101.Yang Y, Wang Y, Li S, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. 2004;41:171–174. doi: 10.1136/jmg.2003.012153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Cox JJ, Reimann F, Nicholas AK, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444:894–898. doi: 10.1038/nature05413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Goldberg YP, MacFarlane J, MacDonald ML, et al. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet. 2007;71:311–319. doi: 10.1111/j.1399-0004.2007.00790.x. [DOI] [PubMed] [Google Scholar]
  • 104.Nilsen KB, Nicholas AK, Woods CG, Mellgren SI, Nebuchennykh M, Aasly J. Two novel SCN9A mutations causing insensitivity to pain. Pain. 2009;143:155–158. doi: 10.1016/j.pain.2009.02.016. [DOI] [PubMed] [Google Scholar]
  • 105.Ahmad S, Dahllund L, Eriksson AB, et al. A stop codon mutation in SCN9A causes lack of pain sensation. Hum Mol Genet. 2007;16:2114–2121. doi: 10.1093/hmg/ddm160. [DOI] [PubMed] [Google Scholar]
  • 106.Drenth JP, Waxman SG. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest. 2007;117:3603–3609. doi: 10.1172/JCI33297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Cheng X, Dib-Hajj SD, Tyrrell L, Waxman SG. Mutation I136V alters electrophysiological properties of the Na(v)1.7 channel in a family with onset of erythromelalgia in the second decade. Mol Pain. 2008;4:1–1. doi: 10.1186/1744-8069-4-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Choi JS, Dib-Hajj SD, Waxman SG. Inherited erythermalgia: limb pain from an S4 charge-neutral Na channelopathy. Neurology. 2006;67:1563–1567. doi: 10.1212/01.wnl.0000231514.33603.1e. [DOI] [PubMed] [Google Scholar]
  • 109.Cummins TR, Dib-Hajj SD, Waxman SG. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J Neurosci. 2004;24:8232–8236. doi: 10.1523/JNEUROSCI.2695-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Dib-Hajj SD, Rush AM, Cummins TR, et al. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain. 2005;128:1847–1854. doi: 10.1093/brain/awh514. [DOI] [PubMed] [Google Scholar]
  • 111.Han C, Rush AM, Dib-Hajj SD, et al. Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7. Ann Neurol. 2006;59:553–558. doi: 10.1002/ana.20776. [DOI] [PubMed] [Google Scholar]
  • 112.Harty TP, Dib-Hajj SD, Tyrrell L, et al. Na(V)1.7 mutant A863P in erythromelalgia: effects of altered activation and steady-state inactivation on excitability of nociceptive dorsal root ganglion neurons. J Neurosci. 2006;26:12566–12575. doi: 10.1523/JNEUROSCI.3424-06.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Lampert A, Dib-Hajj SD, Tyrrell L, Waxman SG. Size matters: Erythromelalgia mutation S241T in Nav1.7 alters channel gating. J Biol Chem. 2006;281:36029–36035. doi: 10.1074/jbc.M607637200. [DOI] [PubMed] [Google Scholar]
  • 114.Sheets PL, Jackson JO, Waxman SG, Dib-Hajj SD, Cummins TR. A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity. J Physiol. 2007;581:1019–1031. doi: 10.1113/jphysiol.2006.127027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Dib-Hajj SD, Yang Y, Waxman SG. Genetics and molecular pathophysiology of Na(v)1.7-related pain syndromes. Adv Genet. 2008;63:85–110. doi: 10.1016/S0065-2660(08)01004-3. [DOI] [PubMed] [Google Scholar]
  • 116.Jarecki BW, Sheets PL, Jackson IIJO, Cummins TR. Paroxysmal Extreme Pain Disorder mutations within the D3/S4-S5 Linker of Nav1.7 cause moderate destabilization of fast-inactivation. J Physiol 2008:jphysiol.2008.154906. [DOI] [PMC free article] [PubMed]
  • 117.Zimmermann K, Leffler A, Babes A, et al. Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures. Nature. 2007;447:855–858. doi: 10.1038/nature05880. [DOI] [PubMed] [Google Scholar]
  • 118.Abrahamsen B, Zhao J, Asante CO, et al. The Cell and Molecular Basis of Mechanical, Cold, and Inflammatory Pain. Science. 2008;321:702–705. doi: 10.1126/science.1156916. [DOI] [PubMed] [Google Scholar]
  • 119.Okuse K, Chaplan SR, McMahon SB, et al. Regulation of expression of the sensory neuron-specific sodium channel SNS in inflammatory and neuropathic pain. Mol Cell Neurosci. 1997;10:196–207. doi: 10.1006/mcne.1997.0657. [DOI] [PubMed] [Google Scholar]
  • 120.Decosterd I, Ji RR, Abdi S, Tate S, Woolf CJ. The pattern of expression of the voltage-gated sodium channels Na(v)1.8 and Na(v)1.9 does not change in uninjured primary sensory neurons in experimental neuropathic pain models. Pain. 2002;96:269–277. doi: 10.1016/S0304-3959(01)00456-0. [DOI] [PubMed] [Google Scholar]
  • 121.Novakovic SD, Tzoumaka E, McGivern JG, et al. Distribution of the tetrodotoxin-resistant sodium channel PN3 in rat sensory neurons in normal and neuropathic conditions. J Neurosci. 1998;18:2174–2187. doi: 10.1523/JNEUROSCI.18-06-02174.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Dong XW, Goregoaker S, Engler H, et al. Small interfering RNA-mediated selective knockdown of Na(V)1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats. Neuroscience. 2007;146:812–821. doi: 10.1016/j.neuroscience.2007.01.054. [DOI] [PubMed] [Google Scholar]
  • 123.Joshi SK, Mikusa JP, Hernandez G, et al. Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain. 2006;123:75–82. doi: 10.1016/j.pain.2006.02.011. [DOI] [PubMed] [Google Scholar]
  • 124.Lai J, Gold MS, Kim CS, et al. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain. 2002;95:143–152. doi: 10.1016/S0304-3959(01)00391-8. [DOI] [PubMed] [Google Scholar]
  • 125.Roza C, Laird JM, Souslova V, Wood JN, Cervero F. The tetrodotoxin-resistant Na+ channel Nav1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J Physiol. 2003;550:921–926. doi: 10.1113/jphysiol.2003.046110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Cummins TR, Dib-Hajj SD, Black JA, Akopian AN, Wood JN, Waxman SG. A novel persistent tetrodotoxin-resistant sodium current in SNS-null and wild-type small primary sensory neurons. J Neurosci. 1999;19:RC43–RC43. doi: 10.1523/JNEUROSCI.19-24-j0001.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Dib-Hajj SD, Tyrrell L, Cummins TR, Black JA, Wood PM, Waxman SG. Two tetrodotoxin-resistant sodium channels in human dorsal root ganglion neurons. FEBS Lett. 1999;462:117–120. doi: 10.1016/S0014-5793(99)01519-7. [DOI] [PubMed] [Google Scholar]
  • 128.Dib-Hajj S, Black JA, Cummins TR, Waxman SG. NaN/Nav1.9: a sodium channel with unique properties. Trends Neurosci. 2002;25:253–259. doi: 10.1016/S0166-2236(02)02150-1. [DOI] [PubMed] [Google Scholar]
  • 129.Dib-Hajj SD, Tyrrell L, Black JA, Waxman SG. NaN, a novel voltage-gated Na channel, is expressed preferentially in peripheral sensory neurons and down-regulated after axotomy. Proc Natl Acad Sci U S A. 1998;95:8963–8968. doi: 10.1073/pnas.95.15.8963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Tate S, Benn S, Hick C, et al. Two sodium channels contribute to the TTX-R sodium current in primary sensory neurons. Nat Neurosci. 1998;1:653–655. doi: 10.1038/3652. [DOI] [PubMed] [Google Scholar]
  • 131.Porreca F, Lai J, Bian D, et al. A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc Natl Acad Sci U S A. 1999;96:7640–7644. doi: 10.1073/pnas.96.14.7640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132.Priest BT, Murphy BA, Lindia JA, et al. Contribution of the tetrodotoxjn-resistant voltage-gated sodium channel NaV1.9 to sensory transmission and nociceptive behavior. Proc Natl Acad Sci U S A. 2005;102:9382–9387. doi: 10.1073/pnas.0501549102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Smith ESJ, Momin A. Persistent pain: the contribution of NaV1.9. J Physiol 2008:jphysiol.2008.152520. [DOI] [PMC free article] [PubMed]
  • 134.Jarvis MF, Honore P, Shieh CC, et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci U S A. 2007;104:8520–8525. doi: 10.1073/pnas.0611364104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135.Kort ME, Drizin I, Gregg RJ, et al. Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. J Med Chem. 2008;51:407–416. doi: 10.1021/jm070637u. [DOI] [PubMed] [Google Scholar]
  • 136.McGaraughty S, Chu KL, Scanio MJ, Kort ME, Faltynek CR, Jarvis MF. A selective Nav1.8 sodium channel blocker, A-803467 [5-(4-chlorophenyl-N-(3,5-dimethoxyphenyl)furan-2-carboxamide], attenuates spinal neuronal activity in neuropathic rats. J Pharmacol Exp Ther. 2008;324:1204–1211. doi: 10.1124/jpet.107.134148. [DOI] [PubMed] [Google Scholar]
  • 137.Felix JP, Williams BS, Priest BT, et al. Functional assay of voltage-gated sodium channels using membrane potential-sensitive dyes. Assay Drug Dev Technol. 2004;2:260–268. doi: 10.1089/1540658041410696. [DOI] [PubMed] [Google Scholar]
  • 138.Hoyt SB, London C, Gorin D, et al. Discovery of a novel class of benzazepinone Na(v)1.7 blockers: potential treatments for neuropathic pain. Bioorg Med Chem Lett. 2007;17:4630–4634. doi: 10.1016/j.bmcl.2007.05.076. [DOI] [PubMed] [Google Scholar]
  • 139.Hoyt SB, London C, Ok H, et al. Benzazepinone Na(v)1.7 blockers: Potential treatments for neuropathic pain. Bioorg Med Chem Lett 2007. [DOI] [PubMed]
  • 140.Williams BS, Felix JP, Priest BT, et al. Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. Biochemistry. 2007;46:14693–14703. doi: 10.1021/bi7018207. [DOI] [PubMed] [Google Scholar]
  • 141.London C, Hoyt SB, Parsons WH, et al. Imidazopyridines: a novel class of hNav1.7 channel blockers. Bioorg Med Chem Lett. 2008;18:1696–1701. doi: 10.1016/j.bmcl.2008.01.047. [DOI] [PubMed] [Google Scholar]
  • 142.Liu CJ, Priest BT, Bugianesi RM, et al. A high-capacity membrane potential FRET-based assay for NaV1.8 channels. Assay Drag Dev Technol. 2006;4:37–48. doi: 10.1089/adt.2006.4.37. [DOI] [PubMed] [Google Scholar]
  • 143.Trivedi S, Dekermendjian K, Julien R, et al. Cellular HTS Assays for Pharmacological Characterization of Na(V)1.7 Modulators. Assay Drug Dev Technol 2007. [DOI] [PubMed]
  • 144.Vickery RG, Amagasu SM, Chang R, et al. Comparison of the pharmacological properties of rat Na(V)1.8 with rat Na(V)1.2a and human Na(V)1.5 voltage-gated sodium channel subtypes using a membrane potential sensitive dye and FLIPR. Receptors Channels. 2004;10:11–23. doi: 10.1080/10606820490270410. [DOI] [PubMed] [Google Scholar]
  • 145.Benjamin ER, Pruthi F, Olanrewaju S, et al. State-dependent compound inhibition of Nav1.2 sodium channels using the FLIPR Vm dye: on-target and off-target effects of diverse pharmacological agents. J Biomol Screen. 2006;11:29–39. doi: 10.1177/1087057105280918. [DOI] [PubMed] [Google Scholar]
  • 146.Bhattacharya A, Wang Q, Wu N, Chaplan SR, Wickenden AD. Assay dependent activity of the sodium channel gating modifier protoxin-I: implications for sodium channel drug discovery. In: Experimental Biology; 2009; New Orleans, LA, 2009.
  • 147.Middleton RE, Warren VA, Kraus RL, et al. Two tarantula peptides inhibit activation of multiple sodium channels. Biochemistry. 2002;41:14734–14747. doi: 10.1021/bi026546a. [DOI] [PubMed] [Google Scholar]
  • 148.Castle N, Printzenhoff D, Zellmer S, Antonio B, Wickenden A, Silvia C. Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms. Comb Chem High Throughput Screen. 2009;12:107–122. doi: 10.2174/138620709787047993. [DOI] [PubMed] [Google Scholar]
  • 149.Schmalhofer W, Calhoun J, Burrows R, et al. ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. Mol Pharmacol 2008:mol.108.047670. [DOI] [PubMed]
  • 150.Escoubas P, Bosmans F. Spider peptide toxins as leads for drug development. Expert Opinion on Drug Discovery. 2007;2:823–835. doi: 10.1517/17460441.2.6.823. [DOI] [PubMed] [Google Scholar]
  • 151.Xiao Y, Bingham JP, Zhu W, Moczydlowski E, Liang S, Cummins TR. Tarantula huwentoxin-IV inhibits neuronal sodium channels by binding to receptor site 4 and trapping the domain ii voltage sensor in the closed configuration. J Biol Chem. 2008;283:27300–27313. doi: 10.1074/jbc.M708447200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152.Bosmans F, Martin-Eauclaire MF, Swartz KJ. Deconstructing voltage sensor function and pharmacology in sodium channels. Nature. 2008;456:202–208. doi: 10.1038/nature07473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 153.Sokolov S, Kraus RL, Scheuer T, Catterall WA. Inhibition of Sodium Channel Gating by Trapping the Domain II Voltage Sensor with Protoxin II. Mol Pharmacol. 2008;73:1020–1028. doi: 10.1124/mol.107.041046. [DOI] [PubMed] [Google Scholar]
  • 154.Smith JJ, Cummins TR, Alphy S, Blumenthal KM. Molecular Interactions of the Gating Modifier Toxin ProTx-II with Nav1.5: Implied existence of a novel toxin binding site coupled to activation. J Biol Chem. 2007;282:12687–12697. doi: 10.1074/jbc.M610462200. [DOI] [PubMed] [Google Scholar]
  • 155.Dib-Hajj SD, Binshtok AM, Cummins TR, Jarvis MF, Samad T, Zimmermann K. Voltage-gated sodium channels in pain states: Role in pathophysiology and targets for treatment. Brain Res Rev. 2009;60:65–83. doi: 10.1016/j.brainresrev.2008.12.005. [DOI] [PubMed] [Google Scholar]
  • 156.Waxman SG. Channel, neuronal and clinical function in sodium channelopathies: from genotype to phenotype. Nat Neurosci. 2007;10:405–409. doi: 10.1038/nn1857. [DOI] [PubMed] [Google Scholar]
  • 157.Cummins TR, Rush AM. Voltage-gated sodium channel blockers for the treatment of neuropathic pain. Expert Rev Neurother. 2007;7:1597–1612. doi: 10.1586/14737175.7.11.1597. [DOI] [PubMed] [Google Scholar]
  • 158.Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: Implications for mechanisms of pain. Pain. 2007;131:243–257. doi: 10.1016/j.pain.2007.07.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 159.Wood JN, Boorman J. Voltage-gated sodium channel blockers; target validation and therapeutic potential. Curr Top Med Chem. 2005;5:529–537. doi: 10.2174/1568026054367584. [DOI] [PubMed] [Google Scholar]
  • 160.Wood JN, Boorman JP, Okuse K, Baker MD. Voltage-gated sodium channels and pain pathways. J Neurobiol. 2004;61:55–71. doi: 10.1002/neu.20094. [DOI] [PubMed] [Google Scholar]
  • 161.England S. Voltage-gated sodium channels: the, search for subtype-selective analgesics. Expert Opinion on Investigational Drugs. 2008;17:1849–1864. doi: 10.1517/13543780802514559. [DOI] [PubMed] [Google Scholar]
  • 162.Momin A, Wood JN. Sensory neuron voltage-gated sodium channels as analgesic drag targets. Curr Opin Neurobiol. 2008;18:383–388. doi: 10.1016/j.conb.2008.08.017. [DOI] [PubMed] [Google Scholar]
  • 163.Priest BT, Kaczorowski GJ. Blocking sodium channels to treat neuropathic pain. Expert Opin Ther Targets. 2007;11:291–306. doi: 10.1517/14728222.11.3.291. [DOI] [PubMed] [Google Scholar]
  • 164.Hargus NJ, Patel MK. Voltage-gated Na+ channels in neuropathic pain. Expert Opinion on Investigational Drugs. 2007;16:635–646. doi: 10.1517/13543784.16.5.635. [DOI] [PubMed] [Google Scholar]
  • 165.Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron. 2000;26:13–25. doi: 10.1016/S0896-6273(00)81133-2. [DOI] [PubMed] [Google Scholar]
  • 166.Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain. 1996;64:293–302. doi: 10.1016/0304-3959(95)00138-7. [DOI] [PubMed] [Google Scholar]
  • 167.Kautio AL, Haanpaa M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage. 2008;35:31–39. doi: 10.1016/j.jpainsymman.2007.02.043. [DOI] [PubMed] [Google Scholar]
  • 168.Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbazepine (tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry. 1966;29:265–267. doi: 10.1136/jnnp.29.3.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 169.Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia. Use of side effects. Arch Neurol. 1968;19:129–136. doi: 10.1001/archneur.1968.00480020015001. [DOI] [PubMed] [Google Scholar]
  • 170.Rull JA, Quibrera R, Gonzalez-Millan H, Lozano Castaneda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia. 1969;5:215–218. doi: 10.1007/BF01212087. [DOI] [PubMed] [Google Scholar]
  • 171.Harke H, Gretenkort P, Ladleif HU, Rahman S, Harke O. The response of neuropathic pain and pain in complex regional pain syndrome 1 to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: a double-blinded randomized study. Anesth Analg. 2001;92:488–495. doi: 10.1097/00000539-200102000-00039. [DOI] [PubMed] [Google Scholar]
  • 172.Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther. 1990;47:305–312. doi: 10.1038/clpt.1990.33. [DOI] [PubMed] [Google Scholar]
  • 173.Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain. 1991;45:3–9. doi: 10.1016/0304-3959(91)90157-S. [DOI] [PubMed] [Google Scholar]
  • 174.Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109–118. doi: 10.1016/j.pain.2005.03.029. [DOI] [PubMed] [Google Scholar]
  • 175.Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346–356. doi: 10.1111/j.1526-4637.2005.00061.x. [DOI] [PubMed] [Google Scholar]
  • 176.Wernicke IF, Pritchett YL, D’Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411–1420. doi: 10.1212/01.wnl.0000240225.04000.1a. [DOI] [PubMed] [Google Scholar]
  • 177.Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain. 2007;23:150–158. doi: 10.1097/01.ajp.0000210957.39621.b2. [DOI] [PubMed] [Google Scholar]
  • 178.Shaibani A, Fares S, Selam IL, et al. Lacosamide in Painful Diabetic Neuropathy: An 18-Week Double-Blind Placebo-Controlled Trial. J Pain 2009. [DOI] [PubMed]
  • 179.Wymer JP, Simpson J, Sen D, Bongardt S. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain. 2009;25:376–385. doi: 10.1097/AJP.0b013e318196d2b6. [DOI] [PubMed] [Google Scholar]
  • 180.Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mullens EL. Lamotrigine (lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain. 1997;73:223–230. doi: 10.1016/S0304-3959(97)00104-8. [DOI] [PubMed] [Google Scholar]
  • 181.McCleane G. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo controlled trial. Pain. 1999;83:105–107. doi: 10.1016/S0304-3959(99)00095-0. [DOI] [PubMed] [Google Scholar]
  • 182.Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001;57:505–509. doi: 10.1212/wnl.57.3.505. [DOI] [PubMed] [Google Scholar]
  • 183.Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology. 2001;56:184–190. doi: 10.1212/wnl.56.2.184. [DOI] [PubMed] [Google Scholar]
  • 184.Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain. 2002;96:375–383. doi: 10.1016/S0304-3959(01)00484-5. [DOI] [PubMed] [Google Scholar]
  • 185.Simpson DM, McArthur JC, Olney R, et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology. 2003;60:1508–1514. doi: 10.1212/01.wnl.0000063304.88470.d9. [DOI] [PubMed] [Google Scholar]
  • 186.Rao RD, Flynn PJ, Sloan JA, et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer. 2008;112:2802–2808. doi: 10.1002/cncr.23482. [DOI] [PubMed] [Google Scholar]
  • 187.Kastrup I, Bach FW, Petersen P, et al. Lidocaine treatment of painful diabetic neuropathy and endogenous opioid peptides in plasma. Clin J Pain. 1989;5:239–244. doi: 10.1097/00002508-198909000-00008. [DOI] [PubMed] [Google Scholar]
  • 188.Ellemann K, Sjogren P, Banning AM, Jensen TS, Smith T, Geertsen P. Trial of intravenous lidocaine on painful neuropathy in cancer patients. Clin J Pain. 1989;5:291–294. doi: 10.1097/00002508-198912000-00003. [DOI] [PubMed] [Google Scholar]
  • 189.Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology. 1991;41:1024–1028. doi: 10.1212/wnl.41.7.1024. [DOI] [PubMed] [Google Scholar]
  • 190.Bruera E, Ripamonti C, Brenneis C, Macmillan K, Hanson J. A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. J Pain Symptom Manage. 1992;7:138–140. doi: 10.1016/S0885-3924(06)80004-7. [DOI] [PubMed] [Google Scholar]
  • 191.Medrik-Goldberg T, Lifschitz D, Pud D, Adler R, Eisenberg E. Intravenous lidocaine, amantadine, and placebo in the treatment of sciatica: a double-blind, randomized, controlled study. Reg Anesth Pain Med. 1999;24:534–540. doi: 10.1097/00115550-199924060-00011. [DOI] [PubMed] [Google Scholar]
  • 192.Wallace MS, Ridgeway BM, Leung AY, Gerayli A, Yaksh TL. Concentration-effect relationship of intravenous lidocaine on the allodynia of complex regional pain syndrome types I and II. Anesthesiology. 2000;92:75–83. doi: 10.1097/00000542-200001000-00017. [DOI] [PubMed] [Google Scholar]
  • 193.Attal N, Gaude V, Brasseur L, et al. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology. 2000;54:564–574. doi: 10.1212/wnl.54.3.564. [DOI] [PubMed] [Google Scholar]
  • 194.Finnerup NB, Biering-Sorensen F, Johannesen IL, et al. Intravenous lidocaine relieves spinal cord injury pain: a randomized controlled trial. Anesthesiology. 2005;102:1023–1030. doi: 10.1097/00000542-200505000-00023. [DOI] [PubMed] [Google Scholar]
  • 195.Tremont-Lukats IW, Hutson PR, Backonja MM. A randomized, double-masked, placebo-controlled pilot trial of extended IV lidocaine infusion for relief of ongoing neuropathic pain. Clin J Pain. 2006;22:266–271. doi: 10.1097/01.ajp.0000169673.57062.40. [DOI] [PubMed] [Google Scholar]
  • 196.Backonja M, Gombar KA. Response of central pain syndromes to intravenous lidocaine. I Pain Symptom Manage. 1992;7:172–178. doi: 10.1016/S0885-3924(06)80010-2. [DOI] [PubMed] [Google Scholar]
  • 197.Attal N, Rouaud J, Brasseur L, Chauvin M, Bouhassira D. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology. 2004;62:218–225. doi: 10.1212/01.wnl.0000103237.62009.77. [DOI] [PubMed] [Google Scholar]
  • 198.Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci. 1999;162:162–168. doi: 10.1016/S0022-510X(98)00322-0. [DOI] [PubMed] [Google Scholar]
  • 199.Chabal C, Jacobson L, Russell LC, Burchiel KJ. Pain responses to perineuromal injection of normal saline, gallamine, and lidocaine in humans. Pain. 1989;36:321–325. doi: 10.1016/0304-3959(89)90091-2. [DOI] [PubMed] [Google Scholar]
  • 200.Chabal C, Jacobson L, Mariano A, Chaney E, Britell CW. The use of oral mexiletine for the treatment of pain after peripheral nerve injury. Anesthesiology. 1992;76:513–517. doi: 10.1097/00000542-199204000-00005. [DOI] [PubMed] [Google Scholar]
  • 201.Stracke H, Meyer UE, Schumacher HE, Federlin K. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care. 1992;15:1550–1555. doi: 10.2337/diacare.15.11.1550. [DOI] [PubMed] [Google Scholar]
  • 202.Chiou-Tan FY, Tuel SM, Johnson JC, Priebe MM, Hirsh DD, Strayer JR. Effect of mexiletine on spinal cord injury dysesthetic pain. Am J Phys Med Rehabil. 1996;75:84–87. doi: 10.1097/00002060-199603000-00002. [DOI] [PubMed] [Google Scholar]
  • 203.Oskarsson P, Ljunggren JG, Lins PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. Diabetes Care. 1997;20:1594–1597. doi: 10.2337/diacare.20.10.1594. [DOI] [PubMed] [Google Scholar]
  • 204.Wright JM, Oki JC, Graves L. Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy. Ann Pharmacother. 1997;31:29–34. doi: 10.1177/106002809703100103. [DOI] [PubMed] [Google Scholar]
  • 205.Wallace MS, Magnuson S, Ridgeway B. Efficacy of oral mexiletine for neuropathic pain with allodynia: a double-blind, placebo-controlled, crossover study. Reg Anesth Pain Med. 2000;25:459–467. doi: 10.1053/rapm.2000.8583. [DOI] [PubMed] [Google Scholar]
  • 206.Saudek CD, Werns S, Reidenberg MM. Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther. 1977;22:196–199. doi: 10.1002/cpt1977222196. [DOI] [PubMed] [Google Scholar]
  • 207.Chadda VS, Mathur MS. Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. I Assoc Physicians India. 1978;26:403–406. [PubMed] [Google Scholar]
  • 208.Galer BS, Twilling LL, Harle J, Cluff RS, Friedman E, Rowbotham MC. Lack of efficacy of riluzole in the treatment of peripheral neuropathic pain conditions. Neurology. 2000;55:971–975. doi: 10.1212/wnl.55.7.971. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES